Food and Drugs Administration

Gastrointenstinal Drugs Advisory Committee

June 25, 2003




The statements contained in this document(s) are those of the product's sponsor, not FDA, and FDA does not necessarily agree with the sponsor's statements. FDA has not made a final determination about the safety or effectiveness of the product described in this document.

Serostim® [somatropin (rDNA orgin) for injection] Indicated for the Treatment of Short Bowel Syndrome in Patients - Proposed Indication, Pamela Joyce, Serono (HTM) (PPT)

Backup Slides Used in Q&A, Serono (HTM) (PPT)

Treatment of Short Bowel Syndrome, Dr. Hugo Gallo-Torres, MD, PhD, PNS, FDA (HTM) (PPT)

Serostim® Questions for AC, Dr. Robert Justice, MD, FDA (HTM) (PPT)